Resultados de Búsqueda
Cabozantinib is recommended, within its marketing authorisation, as an option for treating progressive medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease, ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Cabozantinib and vandetanib are the only systemic treatment options for unresectable, locally advanced or metastatic medullary thyroid cancer. Both drugs are currently available through the Cancer Drugs Fund for progressive and symptomatic disease. Best supportive care is the only other available option for people who cannot have cabozantinib or vandetanib. Clinical trial evidence suggests that cabozantinib is effective in delaying disease progression compared with best supportive care, but may ...
ver más ... 2018Embolization of the superior rectal artery is not recommended for the treatment of hemorrhoids. Current evidence on the safety and efficacy of superior rectal artery embolisation for haemorrhoids is ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Further research should report details of patient selection, and follow‑up efficacy (including symptom relief), need for subsequent treatments, quality of life and safety outcomes for at least 1 year.
ver más ... 2018Tofacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Clinical trial evidence shows that tofacitinib is more effective than placebo for treating moderately to severely active ulcerative colitis. An indirect comparison suggests that for people who have not had a TNF-alpha inhibitor, tofacitinib is more effective than adalimumab and golimumab as maintenance treatment. For people who have had a TNF-alpha inhibitor, tofacitinib is more effective than adalimumab as induction treatment. No other statistically significant differences between tofacitinib ...
ver más ... 2018Strimvelis is recommended, within its marketing authorisation, as an option for treating adenosine deaminase deficiency–severe combined immunodeficiency (ADA–SCID) when no suitable human ...
NICE
National Institute for Health and Clinical Excellence (NICE)
ADA–SCID is a rare and serious condition that is fatal if untreated, and which severely affects the quality of life of people with the condition and their families. Treatment for ADA–SCID includes haematopoietic stem cell transplants (HSCTs). Clinical trial evidence shows that Strimvelis is effective in treating ADA–SCID. Compared with HSCTs, results suggest the main benefits are that more people live after Strimvelis than after a transplant and fewer people develop graft-versus-host ...
ver más ... 2018Endoscopic bipolar radiofrequency ablation is recommended for the treatment of biliary obstruction caused by cancer in the context of research.
NICE
National Institute for Health and Clinical Excellence (NICE)
Current evidence on endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer shows there are serious but well recognised safety concerns. Evidence on efficacy is limited in quality and quantity. Therefore, this procedure should only be used in the context of research, which should include randomised controlled trials. Further research should address: patient selection, relief of biliary obstruction, quality of life and survival.
ver más ... 2018